Affymetrix Inc. and Children’s Research Institute, a not-for-profit medical research member organization of Children’s Hospital and Health System affiliated with Medical College of Wisconsin, announced that they have entered into a five-year strategic alliance. The alliance will help Children’s Research Institute build processing capacity over the next five years to analyze up to 25,000 samples using several different Affymetrix arrays.
The goal of the alliance is to demonstrate the clinical utility of array-based molecular diagnostics, and to leverage arrays to make molecular diagnostic tests better, faster and more economical.
Scientists at Children’s Research Institute will use Affymetrix GeneChip® microarray technology to analyze the genomic information of consenting patients. The large-scale clinical studies are designed to enable researchers to identify the genetic variations associated with common, complex diseases that affect children. The resulting information will be used to develop diagnostics and screening tests to help clinicians and families make more informed decisions.
“The primary objective of Children’s Research Institute is to bring together the best in cutting-edge medical research with the best in established medical treatment for children,” said Robert Kliegman, M.D., executive vice president of Children’s Research Institute.
“We are excited to work together with Affymetrix, as its technology platform for highest-throughput genotyping is critical for our goal of identifying genes and markers for common diseases,” said Ulrich Broeckel, M.D., leading investigator in the Individualized Medicine Institute at Children’s Research Institute.
“The Children’s Research Institute is one of the premier pediatric genetic research facilities in the United States,” said Fred Pollock, director of translational medicine and strategic alliances at Affymetrix. “We are excited about moving forward with this strategic alliance that is designed to accelerate the development of new personalized treatments and tests targeted at the more common diseases affecting our children.”